Harpoon Therapeutics Inc (NASDAQ:HARP) was the target of a significant decline in short interest during the month of August. As of August 31st, there was short interest totalling 159,800 shares, a decline of 11.2% from the July 31st total of 180,000 shares. Based on an average daily volume of 29,100 shares, the days-to-cover ratio is presently 5.5 days. Approximately 1.3% of the company’s stock are short sold.
HARP stock traded down $1.19 during mid-day trading on Friday, hitting $16.28. The company had a trading volume of 6,909 shares, compared to its average volume of 58,344. The firm has a market cap of $429.14 million and a PE ratio of -0.63. The company has a debt-to-equity ratio of 0.12, a quick ratio of 9.47 and a current ratio of 9.47. Harpoon Therapeutics has a 12 month low of $9.07 and a 12 month high of $17.85. The stock’s fifty day moving average price is $13.66 and its two-hundred day moving average price is $12.67.
Harpoon Therapeutics (NASDAQ:HARP) last posted its earnings results on Monday, August 5th. The company reported ($0.49) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.62) by $0.13. The firm had revenue of $1.06 million for the quarter, compared to the consensus estimate of $1.22 million. Equities analysts anticipate that Harpoon Therapeutics will post -2.48 earnings per share for the current year.
Several analysts have commented on HARP shares. Zacks Investment Research raised shares of Harpoon Therapeutics from a “hold” rating to a “buy” rating and set a $15.00 price objective on the stock in a research report on Friday, August 9th. Citigroup reaffirmed a “buy” rating and issued a $23.00 price objective on shares of Harpoon Therapeutics in a research report on Friday, May 24th. Six investment analysts have rated the stock with a buy rating, The stock has a consensus rating of “Buy” and an average target price of $22.00.
A number of institutional investors have recently bought and sold shares of HARP. Fosun International Ltd bought a new stake in Harpoon Therapeutics during the 1st quarter worth approximately $3,062,000. MPM Asset Management LLC bought a new stake in Harpoon Therapeutics during the 1st quarter worth approximately $39,796,000. New Leaf Venture Partners L.L.C. bought a new stake in Harpoon Therapeutics during the 1st quarter worth approximately $27,666,000. Sphera Funds Management LTD. purchased a new position in Harpoon Therapeutics in the 1st quarter worth approximately $3,133,000. Finally, Wells Fargo & Company MN purchased a new position in Harpoon Therapeutics in the 2nd quarter worth approximately $94,000. 56.44% of the stock is currently owned by institutional investors and hedge funds.
Harpoon Therapeutics Company Profile
Harpoon Therapeutics, Inc, a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead TriTAC product candidate is HPN424 that is in Phase I clinical trial for the treatment of metastatic castration-resistant prostate cancer.
See Also: What does a bar chart mean for investors?
Receive News & Ratings for Harpoon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harpoon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.